Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

CRISPR is a gene-editing tool that acts like “molecular scissors,” but using it on cancer is complex. The technology’s biggest impact so far is in research labs, helping scientists understand how ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human immune system is still “mind-blowing” for molecular biologist Joshua Modell of ...

Martin Kampmann’s work, supported by the National Institutes of Science (NIH), maps cellular “decision points” that determine ...

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

Intellia Therapeutics will find it challenging to survive now that its CRISPR gene-editing treatment has been tied to severe, ...

Crispr Therapeutics AG remains undervalued despite recent stock volatility and slow Casgevy commercial uptake, with long-term potential intact. Casgevy's strong clinical data and broad approvals are ...